Skip to main content
Clinical Trials/NCT01406821
NCT01406821CompletedNot Applicable

Randomized, Double-blind Clinical Trial of Platelet Rich Plasma for Treatment of Acute and Chronic Patellar Tendinosis

Stanford University3 sites in 1 country30 target enrollmentStarted: August 2009Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
30
Locations
3
Primary Endpoint
Patient-reported improvement in symptoms at 12 weeks

Study Overview

Brief Summary

Platelet rich plasma has been used in previous studies to stimulate faster healing of torn ligaments and tendons in order to help reduce pain and restore normal function. This study aims to prove that non-operative treatment of acute and chronic ligament and tendon injuries with platelet rich plasma will reduce the time needed for participants to heal these injuries and restore function.

We are currently enrolling patients with PATELLAR TENDON INJURIES in the KNEE.

Detailed Description

Pre-procedure diagnosis: The appropriate clinical evaluation will be dictated by the examining physician. Minimal pre-procedure studies will include plain radiographs and MRI. All patients will complete a pretreatment questionnaire.

Patients will be randomized and blinded to a treatment regimen.

Method of randomization: Some of the participating subjects will receive platelet rich plasma and others will receive a saline injection. The platelet rich plasma experimental group will have up to 50cc of whole blood collected via venipuncture and prepared using the standard PRP protocol.

To blind the control group these patients will have a simulated needle stick and approximately 10 ml (2 teaspoons) of blood will be drawn. No blood will be given back to the patient. For those in the control group their ligament or tendon will be stimulated with dry needling (moving a needle up and down in the tendon, without injection). Patients in the PRP treatment group will also have dry needling, plus the PRP will be injected into the tendon as well.

Platelet rich plasma injections have an equivalent risk profile to routine injections. Those potential risks include skin discoloration, pain at injection site, superficial or deep infection, no relief of symptoms, worsening of symptoms, and damage to nerve and blood vessels. Potential benefits include significant improvement in symptoms and reduction in time for return to function.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Acute or chronic ligament or tendon injuries

Exclusion Criteria

  • Pregnant women,
  • children,
  • other injuries that require surgical intervention,
  • associated fractures,
  • systemic disease resulting in an immunocompromised state affecting ability to heal soft tissues

Arms & Interventions

Dry needling

Sham Comparator

Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.

Intervention: Ultrasound-guided dry needling (Procedure)

Platelet-rich plasma (PRP)

Experimental

Blood will be drawn, and platelet-rich plasma will be injected into the tendon.

Intervention: Ultrasound-guided platelet-rich-plasma (PRP) injection (Procedure)

Outcomes

Primary Outcomes

Patient-reported improvement in symptoms at 12 weeks

Time Frame: 12 weeks

Secondary Outcomes

  • Reduction in patellar tendinosis by MRI(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jason L. Dragoo

Associate Professor

Stanford University

Study Sites (3)

Loading locations...

Similar Trials